Please login to the form below

Not currently logged in

Kite Pharma appoints cancer immunotherapy experts

Ronald Levy, Zelig Eshhar and Inder Verma will offer expert advice to US biotech

Ronald Levy, Kite Pharma Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.

Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.

Their expertise will help the US biotech develop medicines that activate the body's T cells to fight tumours.

Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.

"Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said Dr Aya Jakobovits, president and CEO of Kite.

Article by
Thomas Meek

12th August 2013


Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....